TITLE:
Morbid Obesity in Diabetes Mellitus Type 2 and Exenatide
AUTHORS:
María Angeles Ibañez Gil, Alfonso López Ruiz, Alicia Hernández Torres, Ana Belén Hernández Cascales, Pedro Pujante Alarcon, María Dolores Hellín Gil
KEYWORDS:
Type 2 Diabetes and Obesity; Exenatide
JOURNAL NAME:
Pharmacology & Pharmacy,
Vol.5 No.2,
February
10,
2014
ABSTRACT: Worldwide, the prevalence of diabetes
and obesity is increasing in recent years in developed countries. The first
step of treatment is changes in lifestyle and in case of
failure to initiate drug treatment. In our case, the patient with morbid obesity
and glucose intolerance to metformin therapy was initiated without achieving
weight loss and loss of glycemic control after 6 months of treatment. It was
decided to add exenatide as an alternative to bariatric surgery. At the end of
the study (12 months), it showed a weight reduction of 20.8% (Table 1), 20.83% BMI, glycosylated hemoglobin decrease of
2 points, and improved the lipid profile. So exenatide may
be an acceptable option in the use of patient profile. It would be necessary to seek a new alternative
treatment with minimal side effects and less healthcare costs.